https://www.nasdaq.com/press-release/aldeyra-therapeutics-completes-enrollment-in-part-1-of-the-phase-3-guard-trial-of-adx
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-top-line-results-from-the-phase-3-tranquility-trial-in
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-upcoming-conferences-2021-11-09
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-completion-of-enrollment-in-phase-3-tranquility-trial
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-of-ocular-redness-in
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-third-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-report-third-quarter
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-the-virtual-oppenheimer-fall-healthcare-life
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2021-09
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-second-quarter-2021-financial-results-and-recent
https://www.nasdaq.com/press-release/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-u.s.-food-and-drug-0
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2021-08
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-report-second-quarter
https://www.nasdaq.com/press-release/aldeyra-therapeutics-receives-orphan-drug-designation-from-the-u.s.-food-and-drug
https://www.nasdaq.com/press-release/aldeyra-therapeutics-joins-the-russell-2000r-and-russell-3000r-indexes-2021-07-01
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-fireside-chat-at-the-jefferies-virtual
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-first-quarter-2021-financial-results-and-recent-business
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-report-first-quarter
https://www.nasdaq.com/press-release/aldeyra-therapeutics-inc.-announces-pricing-of-%24125-million-public-offering-of-common
https://www.nasdaq.com/press-release/aldeyra-therapeutics-inc.-announces-proposed-%24125-million-public-offering-of-common
https://www.nasdaq.com/press-release/aldeyra-therapeutics-achieves-statistical-significance-for-primary-endpoint-and-all
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-top-line
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-full-year-2020-financial-results-and-recent-business
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-the-ois-dry-eye-innovation-showcase-on-march-11
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-report-full-year-2020
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2021-03
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-the-10th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design-2021
https://www.nasdaq.com/press-release/aldeyra-therapeutics-inc.-announces-closing-of-public-offering-of-common-stock-and
https://www.nasdaq.com/press-release/aldeyra-therapeutics-inc.-announces-pricing-of-public-offering-of-common-stock-2021
https://www.nasdaq.com/press-release/aldeyra-therapeutics-inc.-announces-proposed-public-offering-of-common-stock-2021-01
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-fireside-chat-at-the-h.c.-wainwright
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-positive-top-line-symptom-and-sign-results-from-run-in
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-host-conference-call-and-webcast-to-discuss-top-line-symptom
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-confirmation-of-antiviral-activity-of-adx-1612-2020-12
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-initiation-of-phase-2-clinical-trials-of-adx-629-a
https://www.nasdaq.com/press-release/aldeyra-announces-first-patient-enrolled-in-the-phase-3-tranquility-trial-of
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-the-jefferies-and-a.g.p.-alliance-global
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aldeyra-to-participate-in-the-american-academy-of-ophthalmology-eyecelerator-2020
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-third-quarter-0
https://www.nasdaq.com/press-release/aldeyra-to-present-new-reproxalap-data-from-phase-2-clinical-trial-in-allergic
https://www.nasdaq.com/press-release/aldeyra-to-present-at-oppenheimer-fall-healthcare-life-sciences-medtech-summit-2020
https://www.nasdaq.com/press-release/aldeyra-to-present-at-cantor-and-h.c.-wainwright-virtual-investor-conferences-2020-09
https://www.nasdaq.com/press-release/aldeyra-receives-study-may-proceed-letter-from-fda-to-initiate-clinical-trial-of-adx
https://www.nasdaq.com/press-release/aldeyra-to-participate-in-citis-15th-annual-biopharma-virtual-conference-2020-09-03
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-participate-in-upcoming-virtual-investor-conferences-2020-08
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-second-0
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-stock-sales-to-perceptive-advisors-and-avidity
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-the-ois-virtual-public-company-showcase-on-july-16
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-new-drug-application-nda-development-plans-for-dry-eye
https://www.nasdaq.com/press-release/aldeyra-therapeutics-receives-orphan-medicinal-product-designation-from-the-european
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reaches-agreement-with-the-us-food-and-drug-administration-for
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-2020
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-advance-adx-1612-an-investigational-new-hsp90-inhibitor-with
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-host-conference-call-and-webcast-to-provide-covid-19
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-first-quarter-2020-financial-results-and-announces-new
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-first-quarter
https://www.nasdaq.com/press-release/aldeyra-announces-positive-top-line-phase-1-clinical-trial-results-and-clinical
https://www.nasdaq.com/press-release/aldeyra-to-screen-clinical-stage-compounds-for-activity-in-covid-19-infection-2020-03
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-full-year-2019-financial-results-and-provides-updates-on
https://www.nasdaq.com/press-release/aldeyra-announces-strategic-prioritization-of-late-stage-clinical-pipeline-in-ocular
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-fourth-quarter
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-the-oppenheimer-co.-30th-annual-healthcare
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-provide-update-on-late-stage-clinical-development-pipeline-at
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-host-2020-research-development-day-2020-02-11
https://www.nasdaq.com/press-release/aldeyra-therapeutics-appoints-dr.-paul-karpecki-to-anterior-segment-scientific
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-first-patient-enrolled-in-the-phase-3-invigorate-trial
https://www.nasdaq.com/press-release/aldeyra-therapeutics-appoints-nancy-miller-rich-to-board-of-directors-2020-01-14
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-first-patient-enrolled-in-the-phase-3-guard-trial-for
https://www.nasdaq.com/press-release/aldeyra-therapeutics-announces-positive-top-line-results-from-part-1-of-adaptive
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-host-conference-call-and-webcast-to-announce-top-line-results
https://www.nasdaq.com/press-release/aldeyra-therapeutics-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-third-quarter
https://www.nasdaq.com/press-release/aldeyra-therapeutics-releases-expanded-results-from-allergen-chamber-trial-and
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-host-conference-call-and-webcast-to-release-expanded-results
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-ophthalmology-innovation-summit-at-american
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-phase-3-alleviate-trial-results-in-allergic
https://www.nasdaq.com/press-release/aldeyra-therapeutics-to-present-at-2019-cantor-global-healthcare-conference-2019-09
